SCHEMBL4216248

SCHEMBL4216248

c1ccc(-c2cccc(-c3cccc(-c4ccc5ccccc5n4)c3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.56
NPC1 O15118 12/20 0.56
AR P10275 3/20 0.56
CYP3A4 P08684 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
KDM4E B2RXH2 8/20 0.54
ALDH1A1 P00352 7/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
MAPT P10636 5/20 0.53
HSD17B10 Q99714 4/20 0.53
TP53 P04637 3/20 0.53
PKM P14618 3/20 0.53
HPGD P15428 3/20 0.53
GMNN O75496 1/20 0.53
THPO P40225 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14065141 1.00 RAB9A (0.56) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL4200269 0.98 RAB9A (0.58) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL17449881 0.94 RAB9A (0.62) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL21173048 0.92 RAB9A (0.60) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL17413736 0.92 NPC1 (0.56) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL17343435 0.92 RAB9A (0.49) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL17343383 0.90 ALDH1A1 (0.50) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL22352223 0.90 NPC1 (0.53) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL17945797 0.90 RAB9A (0.54) RAB9ANPC1ARCYP3A4CYP1A2
SCHEMBL25817124 0.89 NPC1 (0.53) RAB9ANPC1ARCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482456-B2 antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol MERCK FROSST CANADA 2009-01-27 US disclosed
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors MERCK FROSST CANADA & CO. (CA) 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors PDE4A, PDE4B, PDE3B RAB9A 1441/4885NPC1 3105/4885AR 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.